Allogene Therapeutics, Inc. (ALLO)
0.8075
-0.03
(-3.72%)
USD |
NASDAQ |
Nov 16, 16:00
0.8075
0.00 (0.00%)
After-Hours: 18:57
Allogene Therapeutics Shareholders Equity (Quarterly) : 392.55M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 392.55M |
| June 30, 2026 | 436.18M |
| March 31, 2026 | 278.88M |
| December 31, 2025 | 292.54M |
| September 30, 2025 | 315.33M |
| June 30, 2025 | 344.56M |
| March 31, 2025 | 385.39M |
| December 31, 2024 | 422.18M |
| September 30, 2024 | 463.75M |
| June 30, 2024 | 515.04M |
| March 31, 2024 | 461.37M |
| December 31, 2023 | 512.23M |
| September 30, 2023 | 583.10M |
| June 30, 2023 | 622.91M |
| March 31, 2023 | 592.26M |
| December 31, 2022 | 665.87M |
| September 30, 2022 | 739.96M |
| June 30, 2022 | 801.95M |
| Date | Value |
|---|---|
| March 31, 2022 | 855.23M |
| December 31, 2021 | 925.20M |
| September 30, 2021 | 969.94M |
| June 30, 2021 | 1.024B |
| March 31, 2021 | 1.070B |
| December 31, 2020 | 1.080B |
| September 30, 2020 | 1.119B |
| June 30, 2020 | 1.163B |
| March 31, 2020 | 606.52M |
| December 31, 2019 | 629.02M |
| September 30, 2019 | 619.72M |
| June 30, 2019 | 655.64M |
| March 31, 2019 | 681.23M |
| December 31, 2018 | 703.16M |
| September 30, 2018 | 242.61M |
| June 30, 2018 | 131.61M |
| March 31, 2018 | |
| December 31, 2017 | 0.003M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Oncolytics Biotech, Inc. | -7.503M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.529B |
| Anixa Biosciences, Inc. | 14.47M |
| Vicapsys Life Sciences, Inc. | -3.549M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 511.32M |
| Total Liabilities (Quarterly) | 118.77M |
| Debt to Equity Ratio | 0.196 |
| Current Ratio | 7.788 |
| Net Debt Paydown Yield | 0.36% |